A new study has confirmed the effectiveness of Prostate-specific Antigen (PSA) screening in reducing prostate cancer mortality.
The retrospective cohort study of over 400,000 men, as published in Elsevier’s Urology® journal,1 set out to re-examine the value of PSA screening, to determine the optimal screening interval and the appropriate age groups to be screened.